Drug Enforcement Administration

Weed Potency Has Increased Dramatically Over Last Several Decades, How High Can THC Limits Go?
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
VP Kamala Harris Urges DEA To Reschedule Cannabis 'As Quickly As Possible,' Calls Prohibition 'Absurd' & 'Unfair'
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
VP Kamala Harris Urges DEA To Reschedule Cannabis 'As Quickly As Possible,' Calls Prohibition 'Absurd' & 'Unfair'
Veteran Organizations Urge Biden And DEA To Reform Cannabis Policy, Citing Health Issues
Is Marijuana A Controlled Substance? Wait… What Is A Controlled Substance?

Drug Enforcement Administration Recent News

35 Cannabis Innovators To Watch In 2024: Leaders Shaping The Green Revolution
Discover the stories and future prospects of 35 influential figures in the cannabis industry, driving innovation and shaping the evolving landscape.
The Fate Of Psilocybin's Rescheduling Petition: DEA Retains Control As Federal Court Confirms Case Jurisdiction
Dr. Sunil Aggarwal’s long-standing battle for the federal rescheduling of psilocybin for end-of-life cancer patients just hit another obstacle.
DEA Renews Effort To Place 2 Psychedelics In Strictest Drug Category
On Dec. 12, the Drug Enforcement Administration (DEA) and the Justice Department jointly released a proposed rule to place 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC) in Schedule I under the federal Controlled Substances Act (CSA).
Should The Biden Administration Reschedule Cannabis By Year-End? Six Governors Say Yes
Six governors call on Biden to reschedule cannabis by year-end, aligning policy with public opinion and boosting economic benefits.
DEA Acknowledges Psychedelics & Cannabis Research Needs, Seeks Production Increases
The Drug Enforcement Administration (DEA) has proposed a considerable surplus to the originally-established 2023 production quotas of cannabinoids and psychedelics toward supporting preclinical and clinical research.
DEA Report Shows Reduced Cannabis Testing Amid Legalization
A recent DEA report highlighted a significant decrease in cannabis testing conducted by drug analysis laboratories, coinciding with the growing wave of marijuana legalization across the U.S.
Congressional Research Service Foresees Potential DEA Endorsement Of Marijuana Rescheduling
On August 29, 2023, the U.S.
Cannabis Valuation Jumps Post-Rescheduling Recommendation, Viridian Report Reveals
In a potentially game-changing decision, the Department of Health and Human Services (HHS) recently recommended the DEA to consider reclassifying cannabis from its Sc
Trulieve CEO: Federal Rescheduling Could Change Heavy Tax Burden For Cannabis Industry
"It's not if, it's just when," said Kim Rivers, CEO of Trulieve Cannabis Corp (OTCQX: TCNNF), regarding the recent recommendation by the Health and Human Services Department (HHS) to the Drug Enforcement Administration (DEA) regarding the 
EXCLUSIVE: Curaleaf Chairman Predicts DEA's Future Steps On Cannabis Rescheduling
"This is a big deal," says Boris Jordan, founder and executive chairman of the board of Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF), referring to the recent recommendation by the Health and Human Services Department (HHS) to the Drug Enforcement Administ
EXCLUSIVE: How Federal Cannabis Reclassification Could Transform Business Finances, Insights From Cresco Labs' CEO
"It's a watershed moment for cannabis," declared Charlie Batchell, the CEO and co-founder of Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF), during an illuminating conversation with Aaron Bry, a content producer at
EXCLUSIVE: End Of Weed Prohibition? Fmr Sen Cory Gardner Discusses Potential Cannabis Reclassification
"This is a new chapter...
Innovator Embraces Psychedelic Horizons With New Schedule 1 Manufacturing License
A new player is entering the psychedelics production space.
At-Home Ketamine Therapy Ending Soon And New Survey Finds Overdosing All Too Common
DEA’s Proposed Telehealth Rules For Prescribing Controlled Substances
These Are The 11 Biggest Psychedelics News And Trends You May Have Missed Last Year
What a year for psychedelics!
USDA Delays Enforcement Of Rules Requiring Hemp To Be Tested By DEA-Registered Labs, Here's Why
Due to the “inadequate” capacity of laboratories certified by the Drug Enforcement Administration (DEA), the U.S. Department of Agriculture (USDA) is delaying the enforcement of a rule requiring hemp to be tested.
DEA Announces How Much Marijuana, MDMA, Psilocyn, LSD, Mescaline, 5-MeO-DMT, MDA, 2-CB Can Be Produced For Research In 2023
The DEA has shared its final production quotas for research drugs for 2023 and is now aiming for further manufacturing goals of several psychedelic compounds than the already substantial increases regarding 2022 initially proposed, 
Psyched: DEA Boosts Research Production, Booker's Psychedelics Reform, Kanye West's George Floyd Comments And More
DEA Boosts Production Of Cannabis & Psychedelics For Research In 2023 The DEA is proposing that 6.7 million grams (14,770 pounds) of marijuana be grown for research, more than double the amount suggested for 2022 (3.2 million grams). 
As DEA Withdraws In Psychedelics Battle Over DOI And DOC, Researchers Win - For Now
The Drug Enforcement Administration (DEA) is pulling back efforts to list certain hallucinogens as Schedule I substances after being challenged by scientists.
Congress: Two New Bills Would Pressure The DEA To Allow Patient Access To Psychedelics And Marijuana
On July 20, bipartisan lawmakers from both chambers of Congress sent companion bills clarifying that federal Right to Try (RTT) laws give terminally-ill patients access to Schedule I substances including mariju
DEA Revokes Project To Schedule 5 New Psychedelic Compounds
Ending last week, the Drug Enforcement Administration (DEA) finally reversed its project to criminalize 5 new psychedelic substances, as first
DEA Taken To Court Again For Access To Psilocybin For End-Of-Life Care
The Drug Enforcement Administration (DEA) has refused once more to a petition from a doctor to treat terminally-ill patients with psilocybin therapy, following federal and state “Right to Try” (RTT) laws. The agency is being takento court in a new case.
Federal Health Officials' Letter To Senators: Psychedelics Illegal Status Limits Research
As reported by Marijuana Moment, officials of the U.S. National Institutes of Health (NIH) replied to two senators’ request for a psychedelics research update with a letter stating that federal prohibit